Aurobindo Pharma gets warning letter from USFDA for manufacturing lapses at API plant

27 Jan 2022 Evaluate

Aurobindo Pharma has received warning letter from US Food and Drug Administration (USFDA) for violating current good manufacturing practice norms at its Telangana-based plant. The significant violations included failure to evaluate the potential effect that changes may have on the quality of intermediates and API.

Hyderabad-based drug firm failed to fully evaluate whether increasing acceptable starting material would impact the quality of the API. The USFDA also pointed at the failure of the company's quality unit to ensure that critical deviations are investigated and resolved.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×